[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].

Date publication

décembre 2012

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NGUYEN Philippe

Tous les auteurs :
Pernod G, Elias A, Gouin I, Gaillard C, Nguyen P, Ouvry P, Sie P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/23122646

Résumé

Rivaroxaban is a direct oral anticoagulant targeting factor Xa. Efficacy and safety of rivaroxaban were evaluated through the phase 3 EINSTEIN program, consisting in three clinical trials regarding the treatment of deep vein thrombosis (EINSTEIN DVT), pulmonary embolism (EINSTEIN PE), and in secondary prevention after a first episode of venous thromboembolic disease (EISNTEIN EXT). Rivaroxaban was recently approved both by the European and the French Health agencies for the treatment of DVT and prevention of deep vein thrombosis recurrence. This report addresses the use of rivaroxaban in clinical practice in such indications.

Référence

J Mal Vasc. 2012 Dec;37(6):300-10